亚虹医药-U
(688176)
| 流通市值：28.75亿 | | | 总市值：44.12亿 |
| 流通股本：3.71亿 | | | 总股本：5.70亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 138,951,629.03 | 80,493,424.46 | 24,319,537.45 | 13,753,343.12 |
| 营业收入 | 138,951,629.03 | 80,493,424.46 | 24,319,537.45 | 13,753,343.12 |
| 二、营业总成本 | 422,331,119.09 | 275,421,295.92 | 117,128,087.84 | 447,147,582.54 |
| 营业成本 | 28,572,333.59 | 17,263,916.71 | 5,115,271.22 | 2,888,452.45 |
| 税金及附加 | 889,515.47 | 515,579.21 | 193,080.87 | 350,702.23 |
| 销售费用 | 131,694,373.01 | 77,758,820.42 | 32,638,884.7 | 34,420,005.17 |
| 管理费用 | 57,774,514.76 | 40,628,225.31 | 21,832,845.76 | 83,134,002.62 |
| 研发费用 | 219,040,308.86 | 154,000,046.06 | 68,099,878.3 | 364,591,785.25 |
| 财务费用 | -15,639,926.6 | -14,745,291.79 | -10,751,873.01 | -38,237,365.18 |
| 其中:利息费用 | 5,031,291.88 | 3,423,186.14 | 736,757.2 | 2,965,500.24 |
| 其中:利息收入 | 23,222,009.91 | 19,115,544.36 | 12,261,459.54 | 42,216,954.31 |
| 加:公允价值变动收益 | 7,618,197.54 | 4,949,183.84 | 2,386,259.17 | 19,584,509.52 |
| 加:投资收益 | 10,197,494.81 | 8,153,122.26 | 7,951,174.26 | 5,807,383.27 |
| 资产处置收益 | 45,298.45 | 45,298.45 | - | - |
| 资产减值损失(新) | -914,953.96 | -914,372.82 | -429,726.42 | -39,007.35 |
| 信用减值损失(新) | -3,441,432.62 | -2,431,292.99 | -915,982.61 | -995,760.62 |
| 其他收益 | 1,214,903.92 | 695,345.46 | 503,764.77 | 5,033,980.12 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -268,659,981.92 | -184,430,587.26 | -83,313,061.22 | -404,003,134.48 |
| 加:营业外收入 | 800 | 800 | - | 2,576,500.01 |
| 减:营业外支出 | 2,898,340.4 | 272,304.18 | - | 76,366.18 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -271,557,522.32 | -184,702,091.44 | -83,313,061.22 | -401,503,000.65 |
| 减:所得税费用 | -215,451.38 | -376,186.75 | -343,675.93 | -668,011.96 |
| 六、净利润 | -271,342,070.94 | -184,325,904.69 | -82,969,385.29 | -400,834,988.69 |
| 持续经营净利润 | -271,342,070.94 | -184,325,904.69 | -82,969,385.29 | -400,834,988.69 |
| 归属于母公司股东的净利润 | -270,840,063.46 | -183,989,894.73 | -82,848,207.86 | -400,434,603.65 |
| 少数股东损益 | -502,007.48 | -336,009.96 | -121,177.43 | -400,385.04 |
| (一)基本每股收益 | -0.48 | -0.32 | -0.15 | -0.7 |
| (二)稀释每股收益 | -0.46 | -0.31 | -0.14 | -0.67 |
| 八、其他综合收益 | -2,291,721.15 | -3,994,091.88 | -1,115,257.61 | 2,100,690.64 |
| 归属于母公司股东的其他综合收益 | -2,230,279.48 | -3,954,135.23 | -1,069,400.13 | 2,063,622.14 |
| 九、综合收益总额 | -273,633,792.09 | -188,319,996.57 | -84,084,642.9 | -398,734,298.05 |
| 归属于母公司股东的综合收益总额 | -273,070,342.94 | -187,944,029.96 | -83,917,607.99 | -398,370,981.51 |
| 归属于少数股东的综合收益总额 | -563,449.15 | -375,966.61 | -167,034.91 | -363,316.54 |
| 公告日期 | 2024-10-30 | 2024-08-29 | 2024-04-30 | 2024-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |